Veracyte, which specializes in genomic cancer testing, announced that the company has completed its acquisition of HalioDx, an immuno-oncology diagnostic company.
HalioDx, which has products in colon and lung cancer, has become a wholly owned subsidiary of Veracyte.
In February, Veracyte announced plans to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers.
